Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market

Neola Medical AB (publ) announces today that the company has been granted a U.S. patent protecting its disposable probes for the medical device Neola®. The advanced light and detector probes are used for continuous lung monitoring of preterm born babies. To monitor both lungs, two probe sets are required and are changed daily, making these disposables central to Neola Medical’s scalable revenue model. The U.S. patent secure proprietary protection in the company’s key target market and complement the already granted European patent. A corresponding application is pending in China.

“These disposables are central to our future business model, where recurring revenues from daily probe replacements are expected to provide significant leverage. Securing patent protection in the U.S. strengthens our competitive position in our most important target market and protects our unique optical design,” says CEO Hanna Sjöström.

About the patent
The granted patent belongs to the patent family “A light diffuser and a method for assembling the same” and protects Neola Medical’s innovation for achieving uniform, diffuse light distribution from the dermal emitter probe. This design is essential for enabling safe, non-invasive, and continuous lung monitoring through optical spectroscopy.